Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported positive topline results from a mid-stage clinical trial that positions its lead drug candidate as a potential first approved treatment for …
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results Read More